Aspirin, NSAIDs, and glioma risk

Original data from the glioma international case-control study and a meta-analysis

E. Susan Amirian, Quinn T. Ostrom, Georgina N. Armstrong, Rose K. Lai, Xiangjun Gu, Daniel I. Jacobs, Ali Jalali, Elizabeth B. Claus, Jill S. Barnholtz-Sloan, Dora Il'Yasova, Joellen M. Schildkraut, Francis Ali-Osman, Siegal Sadetzki, Robert Brian Jenkins, Daniel H Lachance, Sara H. Olson, Jonine L. Bernstein, Ryan T. Merrell, Margaret R. Wrensch, Christoffer Johansen & 6 others Richard S. Houlston, Michael E. Scheurer, Sanjay Shete, Christopher I. Amos, Beatrice Melin, Melissa L. Bondy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: There have been few studies of sufficient size to address the relationship between glioma risk and the use of aspirin or NSAIDs, and results have been conflicting. The purpose of this study was to examine the associations between glioma and aspirin/NSAID use, and to aggregate these findings with prior published studies using meta-analysis. Methods: The Glioma International Case-Control Study (GICC) consists of 4,533 glioma cases and 4,171 controls recruited from 2010 to 2013. Interviews were conducted using a standardized questionnaire to obtain information on aspirin/NSAID use. We examined history of regular use for ≥6 months and duration-response. Restricted maximum likelihood meta-regression models were used to aggregate site-specific estimates, and to combine GICC estimates with previously published studies. Results: A history of daily aspirin use for ≥6 months was associated with a 38% lower glioma risk, compared with not having a history of daily use [adjusted meta-OR ¼ 0.62; 95% confidence interval (CI), 0.54-0.70]. There was a significant duration-response trend (P ¼ 1.67 × 10- 17 ), with lower ORs for increasing duration of aspirin use. Duration-response trends were not observed for NSAID use. In the meta-analysis aggregating GICC data with five previous studies, there was a marginally significant association between use of aspirin and glioma (mOR = 0.84; 95% CI, 0.70-1.02), but no association for NSAID use. Conclusions: Our study suggests that aspirin may be associated with a reduced risk of glioma. Impact: These results imply that aspirin use may be associated with decreased glioma risk. Further research examining the association between aspirin use and glioma risk is warranted.

Original languageEnglish (US)
Pages (from-to)555-562
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume28
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Non-Steroidal Anti-Inflammatory Agents
Glioma
Aspirin
Meta-Analysis
Case-Control Studies
Confidence Intervals
Interviews

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Aspirin, NSAIDs, and glioma risk : Original data from the glioma international case-control study and a meta-analysis. / Susan Amirian, E.; Ostrom, Quinn T.; Armstrong, Georgina N.; Lai, Rose K.; Gu, Xiangjun; Jacobs, Daniel I.; Jalali, Ali; Claus, Elizabeth B.; Barnholtz-Sloan, Jill S.; Il'Yasova, Dora; Schildkraut, Joellen M.; Ali-Osman, Francis; Sadetzki, Siegal; Jenkins, Robert Brian; Lachance, Daniel H; Olson, Sara H.; Bernstein, Jonine L.; Merrell, Ryan T.; Wrensch, Margaret R.; Johansen, Christoffer; Houlston, Richard S.; Scheurer, Michael E.; Shete, Sanjay; Amos, Christopher I.; Melin, Beatrice; Bondy, Melissa L.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 28, No. 3, 01.03.2019, p. 555-562.

Research output: Contribution to journalArticle

Susan Amirian, E, Ostrom, QT, Armstrong, GN, Lai, RK, Gu, X, Jacobs, DI, Jalali, A, Claus, EB, Barnholtz-Sloan, JS, Il'Yasova, D, Schildkraut, JM, Ali-Osman, F, Sadetzki, S, Jenkins, RB, Lachance, DH, Olson, SH, Bernstein, JL, Merrell, RT, Wrensch, MR, Johansen, C, Houlston, RS, Scheurer, ME, Shete, S, Amos, CI, Melin, B & Bondy, ML 2019, 'Aspirin, NSAIDs, and glioma risk: Original data from the glioma international case-control study and a meta-analysis', Cancer Epidemiology Biomarkers and Prevention, vol. 28, no. 3, pp. 555-562. https://doi.org/10.1158/1055-9965.EPI-18-0702
Susan Amirian, E. ; Ostrom, Quinn T. ; Armstrong, Georgina N. ; Lai, Rose K. ; Gu, Xiangjun ; Jacobs, Daniel I. ; Jalali, Ali ; Claus, Elizabeth B. ; Barnholtz-Sloan, Jill S. ; Il'Yasova, Dora ; Schildkraut, Joellen M. ; Ali-Osman, Francis ; Sadetzki, Siegal ; Jenkins, Robert Brian ; Lachance, Daniel H ; Olson, Sara H. ; Bernstein, Jonine L. ; Merrell, Ryan T. ; Wrensch, Margaret R. ; Johansen, Christoffer ; Houlston, Richard S. ; Scheurer, Michael E. ; Shete, Sanjay ; Amos, Christopher I. ; Melin, Beatrice ; Bondy, Melissa L. / Aspirin, NSAIDs, and glioma risk : Original data from the glioma international case-control study and a meta-analysis. In: Cancer Epidemiology Biomarkers and Prevention. 2019 ; Vol. 28, No. 3. pp. 555-562.
@article{f7a2aa9f47be48e2a071fe7f80cc282e,
title = "Aspirin, NSAIDs, and glioma risk: Original data from the glioma international case-control study and a meta-analysis",
abstract = "Background: There have been few studies of sufficient size to address the relationship between glioma risk and the use of aspirin or NSAIDs, and results have been conflicting. The purpose of this study was to examine the associations between glioma and aspirin/NSAID use, and to aggregate these findings with prior published studies using meta-analysis. Methods: The Glioma International Case-Control Study (GICC) consists of 4,533 glioma cases and 4,171 controls recruited from 2010 to 2013. Interviews were conducted using a standardized questionnaire to obtain information on aspirin/NSAID use. We examined history of regular use for ≥6 months and duration-response. Restricted maximum likelihood meta-regression models were used to aggregate site-specific estimates, and to combine GICC estimates with previously published studies. Results: A history of daily aspirin use for ≥6 months was associated with a 38{\%} lower glioma risk, compared with not having a history of daily use [adjusted meta-OR ¼ 0.62; 95{\%} confidence interval (CI), 0.54-0.70]. There was a significant duration-response trend (P ¼ 1.67 × 10- 17 ), with lower ORs for increasing duration of aspirin use. Duration-response trends were not observed for NSAID use. In the meta-analysis aggregating GICC data with five previous studies, there was a marginally significant association between use of aspirin and glioma (mOR = 0.84; 95{\%} CI, 0.70-1.02), but no association for NSAID use. Conclusions: Our study suggests that aspirin may be associated with a reduced risk of glioma. Impact: These results imply that aspirin use may be associated with decreased glioma risk. Further research examining the association between aspirin use and glioma risk is warranted.",
author = "{Susan Amirian}, E. and Ostrom, {Quinn T.} and Armstrong, {Georgina N.} and Lai, {Rose K.} and Xiangjun Gu and Jacobs, {Daniel I.} and Ali Jalali and Claus, {Elizabeth B.} and Barnholtz-Sloan, {Jill S.} and Dora Il'Yasova and Schildkraut, {Joellen M.} and Francis Ali-Osman and Siegal Sadetzki and Jenkins, {Robert Brian} and Lachance, {Daniel H} and Olson, {Sara H.} and Bernstein, {Jonine L.} and Merrell, {Ryan T.} and Wrensch, {Margaret R.} and Christoffer Johansen and Houlston, {Richard S.} and Scheurer, {Michael E.} and Sanjay Shete and Amos, {Christopher I.} and Beatrice Melin and Bondy, {Melissa L.}",
year = "2019",
month = "3",
day = "1",
doi = "10.1158/1055-9965.EPI-18-0702",
language = "English (US)",
volume = "28",
pages = "555--562",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Aspirin, NSAIDs, and glioma risk

T2 - Original data from the glioma international case-control study and a meta-analysis

AU - Susan Amirian, E.

AU - Ostrom, Quinn T.

AU - Armstrong, Georgina N.

AU - Lai, Rose K.

AU - Gu, Xiangjun

AU - Jacobs, Daniel I.

AU - Jalali, Ali

AU - Claus, Elizabeth B.

AU - Barnholtz-Sloan, Jill S.

AU - Il'Yasova, Dora

AU - Schildkraut, Joellen M.

AU - Ali-Osman, Francis

AU - Sadetzki, Siegal

AU - Jenkins, Robert Brian

AU - Lachance, Daniel H

AU - Olson, Sara H.

AU - Bernstein, Jonine L.

AU - Merrell, Ryan T.

AU - Wrensch, Margaret R.

AU - Johansen, Christoffer

AU - Houlston, Richard S.

AU - Scheurer, Michael E.

AU - Shete, Sanjay

AU - Amos, Christopher I.

AU - Melin, Beatrice

AU - Bondy, Melissa L.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background: There have been few studies of sufficient size to address the relationship between glioma risk and the use of aspirin or NSAIDs, and results have been conflicting. The purpose of this study was to examine the associations between glioma and aspirin/NSAID use, and to aggregate these findings with prior published studies using meta-analysis. Methods: The Glioma International Case-Control Study (GICC) consists of 4,533 glioma cases and 4,171 controls recruited from 2010 to 2013. Interviews were conducted using a standardized questionnaire to obtain information on aspirin/NSAID use. We examined history of regular use for ≥6 months and duration-response. Restricted maximum likelihood meta-regression models were used to aggregate site-specific estimates, and to combine GICC estimates with previously published studies. Results: A history of daily aspirin use for ≥6 months was associated with a 38% lower glioma risk, compared with not having a history of daily use [adjusted meta-OR ¼ 0.62; 95% confidence interval (CI), 0.54-0.70]. There was a significant duration-response trend (P ¼ 1.67 × 10- 17 ), with lower ORs for increasing duration of aspirin use. Duration-response trends were not observed for NSAID use. In the meta-analysis aggregating GICC data with five previous studies, there was a marginally significant association between use of aspirin and glioma (mOR = 0.84; 95% CI, 0.70-1.02), but no association for NSAID use. Conclusions: Our study suggests that aspirin may be associated with a reduced risk of glioma. Impact: These results imply that aspirin use may be associated with decreased glioma risk. Further research examining the association between aspirin use and glioma risk is warranted.

AB - Background: There have been few studies of sufficient size to address the relationship between glioma risk and the use of aspirin or NSAIDs, and results have been conflicting. The purpose of this study was to examine the associations between glioma and aspirin/NSAID use, and to aggregate these findings with prior published studies using meta-analysis. Methods: The Glioma International Case-Control Study (GICC) consists of 4,533 glioma cases and 4,171 controls recruited from 2010 to 2013. Interviews were conducted using a standardized questionnaire to obtain information on aspirin/NSAID use. We examined history of regular use for ≥6 months and duration-response. Restricted maximum likelihood meta-regression models were used to aggregate site-specific estimates, and to combine GICC estimates with previously published studies. Results: A history of daily aspirin use for ≥6 months was associated with a 38% lower glioma risk, compared with not having a history of daily use [adjusted meta-OR ¼ 0.62; 95% confidence interval (CI), 0.54-0.70]. There was a significant duration-response trend (P ¼ 1.67 × 10- 17 ), with lower ORs for increasing duration of aspirin use. Duration-response trends were not observed for NSAID use. In the meta-analysis aggregating GICC data with five previous studies, there was a marginally significant association between use of aspirin and glioma (mOR = 0.84; 95% CI, 0.70-1.02), but no association for NSAID use. Conclusions: Our study suggests that aspirin may be associated with a reduced risk of glioma. Impact: These results imply that aspirin use may be associated with decreased glioma risk. Further research examining the association between aspirin use and glioma risk is warranted.

UR - http://www.scopus.com/inward/record.url?scp=85062407156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062407156&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-18-0702

DO - 10.1158/1055-9965.EPI-18-0702

M3 - Article

VL - 28

SP - 555

EP - 562

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 3

ER -